+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Eli Lilly and Co
  • GlaxoSmithKline Inc
  • Lundbeck LLC
  • Pfizer Inc
  • MORE
Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc Key Recent Developments

Feb 04,2020: Neurocrine Biosciences reports fourth quarter and full-year 2019 financial results
Feb 03,2020: Neurocrine Biosciences announces appointment of Shalini Sharp to Board of Directors
Jan 12,2020: Neurocrine Biosciences provides preliminary fourth quarter and full-year 2019 net product sales results and 2020 program Milestones
Dec 03,2019: Neurocrine enters $1.7bn epilepsy therapies deal with Xenon
Nov 04,2019: Neurocrine Biosciences reports third quarter 2019 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Eli Lilly and Co
  • GlaxoSmithKline Inc
  • Lundbeck LLC
  • Pfizer Inc
  • MORE
Section 1 - About the Company
  • Neurocrine Biosciences Inc - Key Facts
  • Neurocrine Biosciences Inc - Key Employees
  • Neurocrine Biosciences Inc - Key Employee Biographies
  • Neurocrine Biosciences Inc - Major Products and Services
  • Neurocrine Biosciences Inc - History
  • Neurocrine Biosciences Inc - Company Statement
  • Neurocrine Biosciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Neurocrine Biosciences Inc - Business Description
  • Neurocrine Biosciences Inc - Corporate Strategy
  • Neurocrine Biosciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Neurocrine Biosciences Inc - Strengths
  • Neurocrine Biosciences Inc - Weaknesses
  • Neurocrine Biosciences Inc - Opportunities
  • Neurocrine Biosciences Inc - Threats
  • Neurocrine Biosciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Neurocrine Biosciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 04, 2020: Neurocrine Biosciences reports fourth quarter and full-year 2019 financial results
  • Feb 03, 2020: Neurocrine Biosciences announces appointment of Shalini Sharp to Board of Directors
  • Jan 12, 2020: Neurocrine Biosciences provides preliminary fourth quarter and full-year 2019 net product sales results and 2020 program Milestones
  • Dec 03, 2019: Neurocrine enters $1.7bn epilepsy therapies deal with Xenon
  • Nov 04, 2019: Neurocrine Biosciences reports third quarter 2019 financial results
  • Sep 30, 2019: Neurocrine Biosciences appoints David W. Boyer as Chief Corporate Affairs Officer
  • Sep 11, 2019: Neurocrine Biosciences announces appointment of Leslie V. Norwalk to board of directors
  • Jul 29, 2019: Neurocrine Biosciences reports second quarter 2019 financial results
  • Apr 29, 2019: Neurocrine Biosciences reports first quarter 2019 financial results
  • Jan 30, 2019: Voyager signs $1.8bn drug development deal with Neurocrine
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Neurocrine Biosciences Inc, Key Facts
  • Neurocrine Biosciences Inc, Key Employees
  • Neurocrine Biosciences Inc, Key Employee Biographies
  • Neurocrine Biosciences Inc, Major Products and Services
  • Neurocrine Biosciences Inc, History
  • Neurocrine Biosciences Inc, Subsidiaries
  • Neurocrine Biosciences Inc, Key Competitors
  • Neurocrine Biosciences Inc, Ratios based on current share price
  • Neurocrine Biosciences Inc, Annual Ratios
  • Neurocrine Biosciences Inc, Interim Ratios
  • Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Neurocrine Biosciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Neurocrine Biosciences Inc, Performance Chart (2015 - 2019)
  • Neurocrine Biosciences Inc, Ratio Charts
  • Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Prometheus Laboratories Inc
  • Pfizer Inc
  • Newron Pharmaceuticals SpA
  • Lundbeck LLC
  • GlaxoSmithKline Inc
  • Eli Lilly and Co
  • Auspex Pharmaceuticals Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
Adroll
adroll